How much profit has DURECT made this year?
DURECT has made -27.54 M USD this year.
DURECT Net Income 2024
DURECT Net Income
-27.54 M USD
Ticker
DRRX
ISIN
US2666051048
WKN
564868
In 2024, DURECT's profit amounted to -27.54 M USD, a -0.29% increase from the -27.62 M USD profit recorded in the previous year.
The DURECT Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 181.1 |
| 2028e | 61.42 |
| 2027e | -12.35 |
| 2026e | -37.04 |
| 2025e | -41.79 |
| 2024e | -27.54 |
| 2023 | -27.62 |
| 2022 | -35.33 |
| 2021 | -36.27 |
| 2020 | -0.58 |
| 2019 | -20.58 |
| 2018 | -25.32 |
| 2017 | -3.7 |
| 2016 | -34.51 |
| 2015 | -22.66 |
| 2014 | -22.11 |
| 2013 | -21.45 |
| 2012 | 16.2 |
| 2011 | -18.77 |
| 2010 | -22.9 |
| 2009 | -30.29 |
| 2008 | -43.91 |
| 2007 | -24.34 |
| 2006 | -33.33 |
| 2005 | -18.13 |
| 2004 | -27.64 |
DURECT Revenue, EBIT, Net Income US2666051048 · 564868
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into DURECT, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DURECT from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DURECT’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of DURECT. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into DURECT’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing DURECT’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DURECT’s growth potential.
DURECT Revenue, EBIT and net profit per share
| Date | DURECT Revenue | DURECT EBIT | DURECT Net Income |
|---|---|---|---|
| 2029e | 286.93 M undefined | 0 undefined | 181.1 M undefined |
| 2028e | 148.03 M undefined | 65.11 M undefined | 61.42 M undefined |
| 2027e | 60.55 M undefined | -13.72 M undefined | -12.35 M undefined |
| 2026e | 23.62 M undefined | -39.11 M undefined | -37.04 M undefined |
| 2025e | 8.74 M undefined | -32.74 M undefined | -41.79 M undefined |
| 2024e | 8.22 M undefined | -26.4 M undefined | -27.54 M undefined |
| 2023 | 8.55 M undefined | -36.88 M undefined | -27.62 M undefined |
| 2022 | 19.28 M undefined | -35.08 M undefined | -35.33 M undefined |
| 2021 | 13.98 M undefined | -34.27 M undefined | -36.27 M undefined |
| 2020 | 30.11 M undefined | -12.62 M undefined | -580,000 undefined |
| 2019 | 25.07 M undefined | -19.94 M undefined | -20.58 M undefined |
| 2018 | 15.28 M undefined | -23.64 M undefined | -25.32 M undefined |
| 2017 | 49.17 M undefined | -2.24 M undefined | -3.7 M undefined |
| 2016 | 14.03 M undefined | -32.36 M undefined | -34.51 M undefined |
| 2015 | 19.12 M undefined | -20.66 M undefined | -22.66 M undefined |
| 2014 | 19.4 M undefined | -21 M undefined | -22.11 M undefined |
| 2013 | 15.33 M undefined | -21.16 M undefined | -21.45 M undefined |
| 2012 | 53.07 M undefined | 16.06 M undefined | 16.2 M undefined |
| 2011 | 33.49 M undefined | -18.85 M undefined | -18.77 M undefined |
| 2010 | 31.59 M undefined | -23.84 M undefined | -22.9 M undefined |
| 2009 | 24.46 M undefined | -30.67 M undefined | -30.29 M undefined |
| 2008 | 28.54 M undefined | -31.19 M undefined | -43.91 M undefined |
| 2007 | 35.64 M undefined | -24.54 M undefined | -24.34 M undefined |
| 2006 | 22.32 M undefined | -31.43 M undefined | -33.33 M undefined |
| 2005 | 28.57 M undefined | -15.63 M undefined | -18.13 M undefined |
| 2004 | 13.85 M undefined | -24.31 M undefined | -27.64 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 13.85 M USD | -24.31 M USD | -27.64 M USD |
| 2005 | 28.57 M USD | -15.63 M USD | -18.13 M USD |
| 2006 | 22.32 M USD | -31.43 M USD | -33.33 M USD |
| 2007 | 35.64 M USD | -24.54 M USD | -24.34 M USD |
| 2008 | 28.54 M USD | -31.19 M USD | -43.91 M USD |
| 2009 | 24.46 M USD | -30.67 M USD | -30.29 M USD |
| 2010 | 31.59 M USD | -23.84 M USD | -22.9 M USD |
| 2011 | 33.49 M USD | -18.85 M USD | -18.77 M USD |
| 2012 | 53.07 M USD | 16.06 M USD | 16.2 M USD |
| 2013 | 15.33 M USD | -21.16 M USD | -21.45 M USD |
| 2014 | 19.4 M USD | -21 M USD | -22.11 M USD |
| 2015 | 19.12 M USD | -20.66 M USD | -22.66 M USD |
| 2016 | 14.03 M USD | -32.36 M USD | -34.51 M USD |
| 2017 | 49.17 M USD | -2.24 M USD | -3.7 M USD |
| 2018 | 15.28 M USD | -23.64 M USD | -25.32 M USD |
| 2019 | 25.07 M USD | -19.94 M USD | -20.58 M USD |
| 2020 | 30.11 M USD | -12.62 M USD | -580,000 USD |
| 2021 | 13.98 M USD | -34.27 M USD | -36.27 M USD |
| 2022 | 19.28 M USD | -35.08 M USD | -35.33 M USD |
| 2023 | 8.55 M USD | -36.88 M USD | -27.62 M USD |
| 2024e | 8.22 M USD | -26.4 M USD | -27.54 M USD |
| 2025e | 8.74 M USD | -32.74 M USD | -41.79 M USD |
| 2026e | 23.62 M USD | -39.11 M USD | -37.04 M USD |
| 2027e | 60.55 M USD | -13.72 M USD | -12.35 M USD |
| 2028e | 148.03 M USD | 65.11 M USD | 61.42 M USD |
| 2029e | 286.93 M USD | 0 USD | 181.1 M USD |
DURECT stock margins US2666051048 · 564868
The DURECT margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DURECT. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DURECT.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the DURECT's sales revenue. A higher gross margin percentage indicates that the DURECT retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the DURECT's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the DURECT's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DURECT's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DURECT. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DURECT's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
DURECT Margin History
| DURECT Gross margin | DURECT Profit margin | DURECT EBIT margin | DURECT Profit margin |
|---|---|---|---|
| 2029e | 79.91 % | 0 % | 63.12 % |
| 2028e | 79.91 % | 43.98 % | 41.49 % |
| 2027e | 79.91 % | -22.65 % | -20.39 % |
| 2026e | 79.91 % | -165.55 % | -156.81 % |
| 2025e | 79.91 % | -374.53 % | -478.12 % |
| 2024e | 79.91 % | -321.23 % | -335.14 % |
| 2023 | 79.91 % | -431.49 % | -323.16 % |
| 2022 | 91.8 % | -181.95 % | -183.25 % |
| 2021 | 85.98 % | -245.14 % | -259.44 % |
| 2020 | 95.35 % | -41.91 % | -1.93 % |
| 2019 | 94.97 % | -79.54 % | -82.09 % |
| 2018 | 89.27 % | -154.71 % | -165.71 % |
| 2017 | 86.52 % | -4.56 % | -7.52 % |
| 2016 | 62.3 % | -230.65 % | -245.97 % |
| 2015 | 79.6 % | -108.05 % | -118.51 % |
| 2014 | 70.72 % | -108.25 % | -113.97 % |
| 2013 | 68.43 % | -138.03 % | -139.92 % |
| 2012 | 91.24 % | 30.26 % | 30.53 % |
| 2011 | 85.91 % | -56.29 % | -56.05 % |
| 2010 | 86.48 % | -75.47 % | -72.49 % |
| 2009 | 78.29 % | -125.39 % | -123.83 % |
| 2008 | 88.19 % | -109.29 % | -153.85 % |
| 2007 | 90.94 % | -68.86 % | -68.29 % |
| 2006 | 85.44 % | -140.82 % | -149.33 % |
| 2005 | 90.13 % | -54.71 % | -63.46 % |
| 2004 | 80.29 % | -175.52 % | -199.57 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 80.29 % | -175.52 % | -199.57 % |
| 2005 | 90.13 % | -54.71 % | -63.46 % |
| 2006 | 85.44 % | -140.82 % | -149.33 % |
| 2007 | 90.94 % | -68.86 % | -68.29 % |
| 2008 | 88.19 % | -109.29 % | -153.85 % |
| 2009 | 78.29 % | -125.39 % | -123.83 % |
| 2010 | 86.48 % | -75.47 % | -72.49 % |
| 2011 | 85.91 % | -56.29 % | -56.05 % |
| 2012 | 91.24 % | 30.26 % | 30.53 % |
| 2013 | 68.43 % | -138.03 % | -139.92 % |
| 2014 | 70.72 % | -108.25 % | -113.97 % |
| 2015 | 79.6 % | -108.05 % | -118.51 % |
| 2016 | 62.3 % | -230.65 % | -245.97 % |
| 2017 | 86.52 % | -4.56 % | -7.52 % |
| 2018 | 89.27 % | -154.71 % | -165.71 % |
| 2019 | 94.97 % | -79.54 % | -82.09 % |
| 2020 | 95.35 % | -41.91 % | -1.93 % |
| 2021 | 85.98 % | -245.14 % | -259.44 % |
| 2022 | 91.8 % | -181.95 % | -183.25 % |
| 2023 | 79.91 % | -431.49 % | -323.16 % |
| 2024e | 79.91 % | -321.23 % | -335.14 % |
| 2025e | 79.91 % | -374.53 % | -478.12 % |
| 2026e | 79.91 % | -165.55 % | -156.81 % |
| 2027e | 79.91 % | -22.65 % | -20.39 % |
| 2028e | 79.91 % | 43.98 % | 41.49 % |
| 2029e | 79.91 % | 0 % | 63.12 % |
DURECT Aktienanalyse
What does DURECT do?
DURECT Corporation is a US pharmaceutical company specializing in the development and marketing of innovative drugs for chronic pain, neurological disorders, and metabolic disorders. They have a broad portfolio of products based on various technologies and platforms, including Parenteral Controlled Release (PCR), Transdermal Delivery Systems (TDS), and Oral Sustained Release (OSR). They have developed technologies such as PCR for slow drug release, TDS for drug administration through the skin, and OSR for sustained-release tablets. DURECT has partnerships with notable pharmaceutical companies such as Pfizer, Sandoz, Zogenix, and Janssen Pharmaceutica, allowing them to distribute their products in a wider market and expand internationally. Their goal is to continue strengthening their position as a leading company in the industry and expanding their product range. DURECT ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding DURECT's Profit Margins
The profit margins of DURECT represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of DURECT's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating DURECT's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
DURECT's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When DURECT’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about DURECT stock
How has the profit developed compared to last year?
The profit has increased by -0.29% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does DURECT publish its earnings?
DURECT publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of DURECT?
The profits of DURECT are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of DURECT?
You can learn more about the earnings of DURECT by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does DURECT pay?
Over the past 12 months, DURECT paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, DURECT is expected to pay a dividend of 0 USD.
What is the dividend yield of DURECT?
The current dividend yield of DURECT is .
When does DURECT pay dividends?
DURECT pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of DURECT?
DURECT paid dividends every year for the past 0 years.
What is the dividend of DURECT?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is DURECT located?
DURECT is assigned to the 'Health' sector.
Wann musste ich die Aktien von DURECT kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of DURECT from 8/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.
When did DURECT pay the last dividend?
The last dividend was paid out on 8/27/2024.
What was the dividend of DURECT in the year 2023?
In the year 2023, DURECT distributed 0 USD as dividends.
In which currency does DURECT pay out the dividend?
The dividends of DURECT are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The DURECT stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von DURECT
Our stock analysis for DURECT Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DURECT Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
